Broadcasting from EULAR 2024 - Frederic Lavie, MD, PhD: cDAPSA Demonstrates Efficacy in Monitoring Disease Activity in PsA
Post hoc analyses of the DISCOVER-1 and DISCOVER-2 trials demonstrated the promising effects of guselkumab, a fully human interleukin (IL)-23p19-subunit inhibitor, on the Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) among a cohort of patients with moderate to high active psoriatic arthritis (PsA).
In an interview with HCPLive, Frederic Lavie, MD, PhD, head of Global Medical Affairs Rheumatology at the Janssen Pharmaceutical Companies of Johnson & Johnson, said the team of investigators sought to validate the composite score that could measure disease activity in these patients in a more simplified approach than what is currently used in clinical trials.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
